Stability of neuraminidase in inactivated influenza vaccines

Vaccine

Volumn 32, Issue 19, 2014, Pages 2225-2230

  Sultana, Ishrat ^a   Yang, Kevin ^a   Getie Kebtie, Melkamu ^a   Couzens, Laura ^a   Markoff, Lewis ^a   Alterman, Michail ^a   Eichelberger, Maryna C ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Immunogenicity; Influenza; Neuraminidase; Stability; Vaccines

Indexed keywords

DETERGENT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME STABILITY; FREEZE THAWING; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; THERMOSTABILITY;

IMMUNOGENICITY; INFLUENZA; NEURAMINIDASE; STABILITY; VACCINES;

ANIMALS; ANTIBODIES, VIRAL; ENZYME STABILITY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; PROTEIN DENATURATION; TEMPERATURE; VACCINE POTENCY; VACCINES, INACTIVATED;

EID: 84897107877     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.078     Document Type: Article

References (19)

1. Couch R.B., Atmar R.L., Franco L.M., Quarles J.M., Wells J., Arden N., et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. Journal of Infectious Diseases 2013, 207:974-981.
2. Couch R.B., Atmar R.L., Keitel W.A., Quarles J.M., Wells J., Arden N., et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 2012, 31(1):190-195.
3. Getie-Kebtie M., Sultana I., Eichelberger M., Alterman M. Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines. Influenza and Other Respiratory Viruses 2013, 7:521-530.
4. Kilbourne E.D., Couch R.B., Kasel J.A., Keitel W.A., Cate T.R., Quarles J.M., et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995, 13(18):1799-1803.
5. Cate T.R., Rayford Y., Nino D., Winokur P., Brady R., Belshe R., et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28(9):2076-2079.
6. Bucher D.J., Kilbourne E.D. A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: determination of molecular size and subunit composition of the active unit. Journal of Virology 1972, 10(1):60-66.
7. Sandbulte M.R., Gao J., Straight T.M., Eichelberger M.C. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza and Other Respiratory Viruses 2009, 3(5):233-240.
8. Williams T.L., Luna L., Guo Z., Cox N.J., Pirkle J.L., Donis R.O., et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008, 26(20):2510-2520.
9. Williams T.L., Pirkle J.L., Barr J.R. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry. Vaccine 2012, 30(14):2475-2482.
10. Lambre C.R., Terzidis H., Greffard A., Webster R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. Journal of Immunological Methods 1990, 135(1/2):49-57.
11. Brett I.C., Johansson B.E. Variation in the divalent cation requirements of influenza A virus N1 neuraminidases. Journal of Biochemistry 2006, 139(3):439-447.
12. Yu Y.Q., Gilar M., Lee P.J., Bouvier E.S., Gebler J.C. Enzyme-friendly, mass spectrometry-compatible surfactant for in-solution enzymatic digestion of proteins. Analytical Chemistry 2003, 75(21):6023-6028.
13. Sultana I., Gao J., Markoff L., Eichelberger M.C. Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. Vaccine 2011, 29(14):2601-2606.
14. Johansson B.E., Grajower B., Kilbourne E.D. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993, 11(10):1037-1039.
15. Kilbourne E.D., Pokorny B.A., Johansson B., Brett I., Milev Y., Matthews J.T. Protection of mice with recombinant influenza virus neuraminidase. Journal of Infectious Diseases 2004, 189(3):459-461.
16. Johansson B.E., Bucher D.J., Kilbourne E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. Journal of Virology 1989, 63(3):1239-1246.
17. Johansson B.E., Matthews J.T., Kilbourne E.D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998, 16(9/10):1009-1015.
18. Burmeister W.P., Cusack S., Ruigrok R.W. Calcium is needed for the thermostability of influenza B virus neuraminidase. Journal of General Virology 1994, 75(Pt 2):381-388.
19. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases 2012, 12(1):36-44.